Peplin to raise $10 million for skin cancer trial

By Helen Schuller
Thursday, 15 December, 2005

Peplin (ASX:PEP) will raise AUD$10 million through a placement to fund phase IIb clinical trials of its lead product, PEP005 Topical, in actinic keratosis (AK), also known as solar keratosis, a skin condition which can develop into skin cancer.

The trial is expected to start in the first half of 2006 and will be conducted at sites in Australia and the US. The trial follows positive results from the phase IIa trial, which showed that PEP005 was well tolerated by patients and had a favourable safety profile, with the majority of local skin reactions mild to moderate.

Peplin currently has three phase IIa clinical trials of PEP005 Topical in progress. These include two clinical trials in basal cell carcinoma (BCC), the most common form of skin cancer. Results of the first of these trials is due to be reported in April 2006.

The company will complete a placement of 14.3 million shares to institutional investors at $0.70 per share. At time of writing Peplin shares were trading at $0.70.

Related News

Free meningococcal B vaccines coming to the NT

The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd